WASHINGTON - A drug used to treat rheumatoid arthritis has been found effective in reducing inflammation in patients with Graves' eye disease after steroids failed.
Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye. The symptoms include pronounced bulging eyes, retracted eyelids, dry eyes, and, in severe cases, loss of vision. Women are more likely than men to develop the disease.
The study suggests that drug rituximab is a potentially effective new treatment for the most severe forms of Graves' eye disease.
"These patients had already received the maximum level of steroid treatment," Dr Raymond S. Douglas, an oculoplastics specialist who recently joined the faculty of the U-M Kellogg Eye Centre.
"Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery," Douglas added.
In the current study, Douglas observed improvement among the patients, four of whom were women, as early as four weeks following the first infusion of rituximab.
They also found that positive results were sustained 4 to 6 months after treatment.
"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," said Douglas.
High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment.
"But these are imperfect options because inflammation often recurs when the treatment ends," Douglas added.
He is hopeful that rituximab can offer sustained improvement.
The study appears online in journal Ophthalmology. (ANI)
Related News
Blue light-filtering lens may protect against age-related vision lossOctober 27th, 2009 WASHINGTON - A new study has shown that implantation of blue light-filtering intraocular lens (IOLs) at the time of cataract surgery increases a nutritional component of the eye, which may offer protection against the development or progression of age-related macular degeneration (AMD). The study has been conducted by leading ophthalmology and vision researchers from the Macular Pigment Research Group at the Waterford Institute of Technology.
Fetal tissue helps restore partial vision in the blindOctober 21st, 2009 WASHINGTON - In a novel study, researchers have successfully improved vision in people with blinding eye diseases by transplanting fetal tissue in the eye. Another experiment showed that retinal prosthesis could also restore some vision in patients with blinding eye disease.
FDA launches plan to track negative side effects of laser vision-correction surgeryOctober 15th, 2009 FDA to study negative effects of Lasik eye surgeryWASHINGTON — The Food and Drug Administration announced plans Thursday to study the scope of problems connected with laser eye-correcting surgery, which include blurred vision and dry eyes. The FDA says it will work with the National Eye Institute and the Department of Defense to determine the percentage of patients who experience negative side effects following surgery.
Cure for glaucoma soon, says new researchOctober 6th, 2009 TORONTO - Cure for glaucoma which leads to blindness may be on its way. Canadian researchers have discovered an unidentified form of circulation in the human eye which may provide important clues to glaucoma.
Gene variant linked to glaucoma identifiedSeptember 22nd, 2009 WASHINGTON - Researchers have discovered gene variants for glaucoma. The international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, claims the discovery could lead to future treatments or a cure for the disease.
Now, device that finds early signs of eye disease in preemiesSeptember 22nd, 2009 WASHINGTON - Researchers at Duke University Medical Center have developed a device that finds early signs of eye disease in premature babies. The technology uses spectral domain optical coherence tomography (SD OCT) to create a 3-D picture of the back of the eye.
Steroid injections offer 'vision restoration' hope for patients with blocked eye veinsSeptember 15th, 2009 WASHINGTON - The injections of the steroid corticosteroid triamcinolone may help restore vision in some patients with retinal vein occlusion, an important cause of vision loss that results from blockages in the blood vessels in the retina, say two research papers. Retinal vein occlusion is an important cause of vision loss worldwide, according to background information in the articles published in the September issue of Archives of Ophthalmology.
UAE charity launches eye care initiative in MoroccoSeptember 5th, 2009 ABU DHABI - The United Arab Emirates Red Crescent Authority (UAE-RCA) has launched the Emirates Anti-Glaucoma Initiative in Morocco, WAM news agency reported Saturday. The initiative plans to treat 4,000 people over next five years in five phases.
ISTA Pharma says Xibrom QD eliminated eye inflammation and eye pain after cataract surgeryAugust 26th, 2009 ISTA says daily Xibrom eye drops met goal in studyIRVINE, Calif. — ISTA Pharmaceuticals Inc.
